Prevalence of NTRK1/3 fusions in mismatch repair-deficient (dMMR)/microsatellite instable (MSI) tumors of patients with metastatic colorectal cancer (mCRC).

被引：2
|
作者：
Svrcek, Magali
Colle, Raphael
Cayre, Anne
Bourgoin, Pierre
Cohen, Romain
Andre, Thierry
Penault-Llorca, Frederique Madeleine
Radosevic-Robin, Nina
机构：
[1] Siric Curamus, Team Microsatellite Instabil & Canc, Inserm Umrs 938, Paris, France
[2] AP HP, Paris, France
[3] Univ Clermont Auvergne, Ctr Jean Perrin, Dept Pathol, INSERM U1240, Clermont Ferrand, France
[4] Sorbonne Univ, INSERM, Microsatellite Instabil & Canc, SIRIC CURAMUS,UMRS 938, Paris, France
[5] Sorbonne Univ, St Antoine Hosp, AP HP, Dept Med Oncol, Paris, France
[6] Ctr Jean Perrin, Clermont Ferrand, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e15537
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15537
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Prevalence of NTRK1/2/3 fusions in dMMR/MSI metastatic colorectal cancer
    Svrcek, M.
    Colle, R.
    Cayre, A.
    Mas, L.
    Bourgoin, P.
    Cohen, R.
    Andre, T.
    Penault-Llorca, F.
    Radosevic-Robin, N.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S556 - S556
  • [2] Response to pembrolizumab in patients with mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC).
    Leal, Alexis Diane
    Paludo, Jonas
    Finnes, Heidi D.
    Grothey, Axel
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [3] Prevalence, treatment and survival of NTRK gene fusions in microsatellite instable metastatic colorectal cancer patients
    Schraa, S.
    Lacle, M. M.
    Zwart, K.
    Gort, E. H.
    Koopman, M.
    de Leng, W.
    Vink, G.
    Bol, G. M.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S703 - S703
  • [4] Pembrolizumab (pembro) for previously treated, microsatellite instabilityehigh (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): Final analysis of KEYNOTE-164
    Le, D. T.
    Diaz, L.
    Kim, T. W.
    Van Cutsem, E.
    Geva, R.
    Jager, D.
    Hara, H.
    Burge, M.
    O'Neil, B.
    Kavan, P.
    Yoshino, T.
    Guimbaud, R.
    Taniguchi, H.
    Elez, E.
    Al-Batran, S-E.
    Boland, P.
    Cui, Y.
    Leconte, P.
    Marinello, P.
    Andre, T.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S550 - S550
  • [5] Early and easy-to-retrieve predictive biomarkers of resistance to immunotherapy in microsatellite instability (MSI)/mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC)
    Vaghi, C.
    Ros Montana, F. J.
    Mambrilla, M.
    Navarro Garces, V.
    Comas, R.
    Salva Ballabrera, F.
    Baraibar Argota, I.
    Saoudi Gonzalez, N.
    Rodriguez Castells, M.
    Garcia Rodriguez, A.
    Alcaraz, A.
    Tabernero, J.
    Elez Fernandez, M. E.
    [J]. ANNALS OF ONCOLOGY, 2024, 35 : S56 - S57
  • [6] SAFETY PROFILE OF NIVOLUMAB plus IPILIMUMAB COMBINATION THERAPY IN PATIENTS WITH DNA MISMATCH REPAIR-DEFICIENT/MICROSATELLITE INSTABILITY-HIGH (DMMR/MSI-H) METASTATIC COLORECTAL CANCER (MCRC) IN CHECKMATE-142
    Brutcher, Edith
    Khoukaz, Taline
    Hartman, Leighanne
    [J]. ONCOLOGY NURSING FORUM, 2018, 45 (02)
  • [7] Nivolumab plus ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): First report of the full cohort from CheckMate-142.
    Andre, Thierry
    Lonardi, Sara
    Wong, Mark
    Lenz, Heinz-Josef
    Gelsomino, Fabio
    Aglietta, Massimo
    Morse, Michael
    Van Cutsem, Eric
    McDermott, Raymond S.
    Hill, Andrew G.
    Sawyer, Michael B.
    Hendlisz, Alain
    Neyns, Bart
    Svrcek, Magali
    Moss, Rebecca Anne
    Ledeine, Jean-Marie
    Cao, Z. Alexander
    Kamble, Shital
    Kopetz, Scott
    Overman, Michael J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [8] RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab combination in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): Results of the GERCOR NIPICOL phase II study
    Cohen, Romain
    Bennouna, Jaafar
    Henriques, Julie
    Tournigand, Christophe
    De La Fouchardiere, Christelle
    Tougeron, David
    Borg, Christophe
    Mazard, Thibault
    Chibaudel, Benoist
    Garcia-Larnicol, Marie-Line
    Svrcek, Magali
    Vernerey, Dewi
    Menu, Yves
    Andre, Thierry
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [9] A phase 3 study of nivolumab (NIVO), NIVO plus ipilimumab (IPI), or chemotherapy for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW
    Andre, T.
    Van Cutsem, E.
    Elez, E.
    Bennouna, J.
    de la Fouchardiere, C.
    Yoshino, T.
    Jensen, L.
    Mendez, G.
    Li, J.
    Goekkurt, E.
    Abdullaev, S.
    Chen, T.
    Lei, M.
    Lonardi, S.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S250 - S250
  • [10] Survival of patients with microsatellite instable (MSI) metastatic colorectal cancer (mCRC) upon systemic non-immunotherapy
    Wensink, G. E.
    Elferink, M. A.
    May, A. M.
    Mol, L.
    Hamers, P. A.
    Punt, C. J.
    Vink, G. R.
    Roodhart, J. M.
    Koopman, M.
    [J]. CANCER RESEARCH, 2019, 79 (13)
12345